| Investor | Sphera Funds Management Ltd. |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Sphera Funds Management Ltd. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-02-05 | 13G/A | 180,697 | ||||||
| 2026-02-05 | 13G/A | OTLK / Outlook Therapeutics, Inc. | 2,571,426 | 3,153,856 | ||||
| 2025-10-23 | 13G/A | PMN / ProMIS Neurosciences, Inc. | 1,892,474 | 3,122,090 | ||||
| 2025-04-10 | 13G/A | OTLK / Outlook Therapeutics, Inc. | 1,714,284 | 2,571,426 | ||||
| 2025-04-10 | 13G/A | SKYE / Skye Bioscience, Inc. | 1,301,518 | 1,476,353 | ||||
| 2025-04-10 | 13G/A | CMMB / Chemomab Therapeutics Ltd. - Depositary Receipt (Common Stock) | 1,214,575 | 900,428 | ||||
| 2025-03-03 | 13G | OTLK / Outlook Therapeutics, Inc. | 1,714,284 | |||||
| 2024-11-04 | 13G/A | JSPR / Jasper Therapeutics, Inc. | 189,270 | |||||
| 2024-08-20 | 13G | CMMB / Chemomab Therapeutics Ltd. - Depositary Receipt (Common Stock) | 1,214,575 | |||||
| 2024-02-08 | 13G | SKYE / Skye Bioscience, Inc. | 1,301,518 | |||||
| 2024-02-05 | 13G/A | / JASPER THERAPEUTICS INC | 5,687,134 | 7,130,625 | ||||
| 2024-02-05 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 8,764,334 | 328,986 | ||||
| 2024-02-05 | 13G/A | INZY / Inozyme Pharma, Inc. | 2,096,258 | 1,562,907 | ||||
| 2024-02-05 | 13G/A | PMN / ProMIS Neurosciences, Inc. | 1,852,518 | 1,892,474 | ||||
| 2023-10-10 | 13G | / JASPER THERAPEUTICS INC | 5,687,134 | |||||
| 2023-08-30 | 13G | PMN / ProMIS Neurosciences, Inc. | 1,852,518 | |||||
| 2023-06-27 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 8,764,334 | 8,764,334 | ||||
| 2023-06-22 | 13G | PRAX / Praxis Precision Medicines, Inc. | 8,764,334 | |||||
| 2023-03-07 | 13G | INZY / Inozyme Pharma, Inc. | 2,096,258 | |||||
| 2023-02-06 | 13G/A | CYCC / Bio Green Med Solution, Inc. | 508,322 | 250,000 | ||||
| 2022-02-14 | 13G/A | ALT / Altimmune, Inc. | 3,775,618 | 1,244,241 | ||||
| 2022-02-14 | 13G/A | CYCC / Bio Green Med Solution, Inc. | 506,824 | 508,322 | ||||
| 2021-08-31 | 13G | ALT / Altimmune, Inc. | 3,775,618 | |||||
| 2021-03-18 | 13G | CYCC / Bio Green Med Solution, Inc. | 506,824 | |||||
| 2021-02-16 | 13G/A | LRMR / Larimar Therapeutics, Inc. | 2,836,367 | 0 | ||||
| 2021-02-16 | 13G/A | ORGS / Orgenesis Inc. | 1,123,090 | 525,216 | ||||
| 2021-02-16 | 13G/A | SIOX / Sio Gene Therapies Inc. | 2,931,017 | 0 | ||||
| 2021-02-16 | 13G/A | XFOR / X4 Pharmaceuticals, Inc. | 970,000 | 250,000 | ||||
| 2021-02-16 | 13G/A | US64052L1061 / Neos Therapeutics, Inc. | 3,530,731 | 0 | ||||
| 2021-02-16 | 13G/A | ALLT / Allot Ltd. | 1,808,196 | 1,129,054 | ||||
| 2020-02-25 | 13G/A | SIOX / Sio Gene Therapies Inc. | 398,540 | 2,931,017 | ||||
| 2020-02-11 | 13G | LRMR / Larimar Therapeutics, Inc. | 2,836,367 | |||||
| 2020-02-11 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 2,788,867 | 1,314,949 | ||||
| 2020-02-11 | 13G/A | XFOR / X4 Pharmaceuticals, Inc. | 845,000 | 970,000 | ||||
| 2020-02-11 | 13G/A | SIOX / Sio Gene Therapies Inc. | 8,200,000 | 398,540 | ||||
| 2020-02-11 | 13G/A | US64052L1061 / Neos Therapeutics, Inc. | 3,711,454 | 3,530,731 | ||||
| 2020-02-11 | 13G/A | ALLT / Allot Ltd. | 1,790,196 | 1,808,196 | ||||
| 2020-02-11 | 13G | EVOK / Evoke Pharma, Inc. | 1,410,946 | 0 | ||||
| 2020-01-28 | 13G | ORGS / Orgenesis Inc. | 1,123,090 | |||||
| 2019-12-31 | 13G | ALLT / Allot Ltd. | 1,790,196 | |||||
| 2019-12-23 | 13G | XFOR / X4 Pharmaceuticals, Inc. | 845,000 | |||||
| 2019-07-02 | 13G | US64052L1061 / Neos Therapeutics, Inc. | 3,711,454 | |||||
| 2019-02-13 | 13G/A | EIGR / Eiger BioPharmaceuticals, Inc. | 511,469 | 87,189 | ||||
| 2019-02-13 | 13G/A | VKTX / Viking Therapeutics, Inc. | 2,145,300 | 770,727 | ||||
| 2019-02-13 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 2,182,712 | 2,788,867 | ||||
| 2019-02-13 | 13G/A | ALDX / Aldeyra Therapeutics, Inc. | 1,159,131 | 1,232,089 | ||||
| 2018-12-20 | 13G | SIOX / Sio Gene Therapies Inc. | 8,200,000 | |||||
| 2018-05-08 | 13G | EVOK / Evoke Pharma, Inc. | 1,410,946 | |||||
| 2018-02-13 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 1,340,588 | 0 | ||||
| 2018-02-13 | 13G/A | ALDX / Aldeyra Therapeutics, Inc. | 783,500 | 1,159,131 | ||||
| 2018-02-13 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 838,200 | 2,182,712 | ||||
| 2018-02-13 | 13G/A | EIGR / Eiger BioPharmaceuticals, Inc. | 447,609 | 511,469 | ||||
| 2017-12-18 | 13G | VKTX / Viking Therapeutics, Inc. | 2,145,300 | |||||
| 2017-08-22 | 13G | EIGR / Eiger BioPharmaceuticals, Inc. | 447,609 | |||||
| 2017-02-21 | 13G | ALDX / Aldeyra Therapeutics, Inc. | 783,500 | |||||
| 2017-02-13 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 1,170,643 | 1,340,588 | ||||
| 2017-02-13 | 13G/A | / Achaogen Inc | 1,571,708 | 514,342 | ||||
| 2017-01-24 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 588,200 | 838,200 | ||||
| 2016-07-06 | 13G | MRNS / Marinus Pharmaceuticals, Inc. | 1,170,643 | |||||
| 2016-06-22 | 13G | VTGN / Vistagen Therapeutics, Inc. | 588,200 | |||||
| 2016-06-13 | 13G | / Achaogen Inc | 1,571,708 | |||||
| 2015-02-26 | 13G/A | ELLO / Ellomay Capital Ltd. | 454,490 | |||||
| 2015-01-15 | 13G/A | ELLO / Ellomay Capital Ltd. | 563,090 | |||||
| 2014-12-02 | 13G | ELLO / Ellomay Capital Ltd. | 558,350 | |||||
| 2013-08-15 | 13G/A | ELLO / Ellomay Capital Ltd. | 496,955 | |||||
| 2013-08-05 | 13G | ELLO / Ellomay Capital Ltd. | 622,300 |
